The AI-driven Drug Discovery industry trends accelerated sharply as 24-month-old startups matured into clinical-stage players. Recursion’s $88 million co-development pact with Roche-Genentech (April 2024) couples its phenomics platform with large-scale chemistry, while Sanofi’s $140 million upfront deal with Insilico Medicine (Dec 2023) advanced an AI-designed INS018_055 into Phase II, validating generative adversarial networks for fibrosis targets. M&A heated up when Charles River paid $150 million for antibody-discovery specialist Vanti Analytics (Feb 2024), adding reinforcement-learning engines to its pre-clinical stack. On the regulatory front, the FDA released a Jan 2024 discussion paper clarifying data-provenance expectations for AI-submitted INDs, nudging sponsors toward audit-ready training sets. Enterprise buying shifted from pilots to multi-year subscriptions, evidenced by BenevolentAI’s £50 million extension with Merck KGaA (Q1 2024). Venture capital remained robust: Genesis Therapeutics closed a $200 million Series B (Mar 2024) to scale its 3-D molecular-propagation platform, and Atomwise secured $42 million to deepen Asian partnerships, signaling sustained investor belief in AI-first pipelines.
